Earnings ·
Immuneering reports Q3 net loss of $24.2M; extends Phase 2 pancreatic cancer trial and expands Phase 3 enrollment
IMRXImmuneering Corp
Immuneering Corporation reported a third-quarter net loss of $24.2 million, or $0.37 per share, compared to a $15.0 million loss in the prior-year period. Research and development expenses rose to $20.7 million from $10.9 million due to higher clinical costs. The company announced that follow-up in its Phase 2 trial for first-line pancreatic cancer is being extended as patients are living longer than projected, with an updated data readout expected in the first half of 2027. Additionally, enrollment in the pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule, prompting an expansion of the target from 510 to 570 patients and potentially accelerating the mid-2028 topline data guidance. Immuneering updated its cash runway to fund operations into the fourth quarter of 2028. The company operates as a late-stage clinical oncology firm developing deep cyclic inhibitors for cancer treatment.